Database : HANSEN
Search on : HANSENOSTATICOS/SANGUE [Subject descriptor]
References found : 2 [refine]
Displaying: 1 .. 2   in format [Detailed]

page 1 de 1

  1 / 2 HANSEN  
              next record last record
select
to print
Id:18103
Author:Desforges, J. F; Thayer, W. W; Dawson, J. P
Title:Hemolytic anemia induced by sulfoxone therapy, with investigations into the mechanisms of its production ?-
Source:Boston; s.n; 1960. 5p p. ilus.
Abstract:A case report is presented of a patient in whom clinical evidence of hemolytic anemia with methemoglobinemia developed upon increasing the dosage of sulfoxone which he was receiving for Hansen's disease. Administration of the drug was withdrawn for six weeks, after which studies were made with the use of radioactive iron to demosntrate the hemolytic effect of sulfoxone. By means of tagging cells of a single age group, it was shown that the suceptibility to hemolysis was related to cell age, and it was only after the red cells had been in the circulation for approximately fifty days that they were subject to the hemolytic effects of this drug. No significant biochemical defect could be demonstrated in the erythrocytes of this patient. However, the decline in activity of glucose-6-phosphate dehydrogenase and glutathione reductase in the aging red cell and the reported sensitivity to this drug of patients with red cell deficiency of glucose-6-phosphate dehydrogenase suggest that the hemolytic mechanism is related to this enzyme system. The case demonstrates that drug-induced hemolytic anemia of this type may occur without demonstrable enzymatic defect of the erythrocytes. The observation that patients appear to compensate for the hemolytic anemia and methemoglobinemia if maintained on this drug may be explained by the fact that the older cells containing less adequate enzyme systems are removed from the circulation and an equilibrium is maintained by increased production of red cells with a shorter age span.
Descriptors:HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/sangue
HANSENOSTATICOS/uso terap
ANEMIA HEMOLITICA/ind quim
ANEMIA HEMOLITICA/diag
ANEMIA HEMOLITICA/etiol
HANSENIASE/clas
 HANSENIASE/compl
 HANSENIASE/diag
 HANSENIASE/terap
Limits:RELATO DE CASO
Location:BR191.1; 00720/s


  2 / 2 HANSEN  
              first record previous record
select
to print
Id:15450
Author:Ryrie, Gordon A.
Title:The therapeutic effects of phthalic acid salts.
Source:Int. J. Lepr;4(2):201-206, Apr.-Jun. 1936. .
Abstract:The magnesium, calcium, potassium-hydrogen and cotarnine salts of phthalic acid have been tried out, on twenty patients each, over a period of six months by intravenous injections twice a week. Intravenous injections of magnesium, calcium and potassium-hydrogen phthalate appear to have no therapeutic effect in leprosy in doses of 20 cc. of a 1 per cent solution. Out of nineteen cases treated with intravenous injections of cotarnine phthalate, in 20 cc. doses, first of a 1 per cent solution and later a 2 per cent solution, twice a week, twelve showed marked improvement, four slight improvement and three no change. The inprovement in these cases occurred only during the first three months of treatment. The clinical improvement appears to be accompanied by a general increase in resistance as indicated by a drop of over 25 per cent in the sedimentation rate of twelve of the patients. It is suggested that the effect of the phthalate group in leprosy is dependent to some extent on the length of time the drug is retained in the body. (AU).
Descriptors:HANSENIASE/quimioter
HANSENOSTATICOS/admin
HANSENOSTATICOS/sangue
HANSENOSTATICOS/hist
HANSENOSTATICOS/farmacol
HANSENOSTATICOS/uso terap
FLUORESCEINAS/admin
 FLUORESCEINAS/uso terap
Limits:HUMANO
Location:BR191.1



page 1 de 1
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information